NCT01590953 is a clinical trial in Obesity, sponsored by Richard Deichmann, MD.

Who is sponsoring NCT01590953?

NCT01590953 is sponsored by Richard Deichmann, MD.

Is NCT01590953 still recruiting?

NCT01590953 is currently completed. Last updated 9 September 2020.

Last reviewed 2020-09-09 · How we verify

NCT01590953

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of the Effects of an Employee Wellness Program

Completed Last updated 9 September 2020

What this trial tests

trial in Obesity in 86 participants. Completed in 21 May 2014.

Timeline

21 May 2012

Primary endpoint
21 May 2014

21 May 2014

Quick facts

Lead sponsor	Richard Deichmann, MD
Status	Completed
Study type	OBSERVATIONAL
Enrollment	86
Start date	21 May 2012
Primary completion	21 May 2014
Estimated completion	21 May 2014
Sites	1 location across United States

Conditions studied

Obesity — all drugs for Obesity →

Sponsor

Richard Deichmann, MD

Who can join

Adults 18 to 90, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Ochsner employees with a body mass index (BMI) greater than or equal to 30 will be enrolled in a fitness program consisting 90 days of a structured exercise program and dietary counseling. Measures of fitness including weight, BMI, cholesterol, HDL, blood pressure, and absenteeism rates will be measured at 0, 90 days, in one year.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01590953 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Richard Deichmann, MD
Last refreshed: 9 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01590953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing